Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Ter Arkh ; 95(7): 580-585, 2023 Sep 29.
Artigo em Russo | MEDLINE | ID: mdl-38159009

RESUMO

Rendu-Osler-Weber disease or hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant disease. It is characterized by vascular dysplasia with the formation of telangiectasias on the skin, mucous membranes of the respiratory and digestive tracts, arteriovenous malformations (AVMs) in the internal organs, which is manifested by bleeding. Diagnosis is based on Curacao criteria: recurrent and spontaneous nosebleeds, multiple telangiectases on the characteristic localizations, AVMs in one or more of the internal organs, a family history of HHT (i.e. first-degree relative who meets these same criteria for definite HHT). Therapy is aimed at preventing and stopping gastrointestinal, nosebleeds, correction of iron deficiency anemia. A promising method of therapy is the use of angiogenesis inhibitors, in particular bevacizumab. The article presents a description of a clinical case of HHT in a 49-year-old woman with telangiectisia on the mucous membrane of the tongue, gastrointestinal tract and liver AVMs.


Assuntos
Anemia Ferropriva , Telangiectasia Hemorrágica Hereditária , Feminino , Humanos , Pessoa de Meia-Idade , Telangiectasia Hemorrágica Hereditária/complicações , Telangiectasia Hemorrágica Hereditária/diagnóstico , Telangiectasia Hemorrágica Hereditária/tratamento farmacológico , Anemia Ferropriva/tratamento farmacológico , Epistaxe/complicações , Epistaxe/tratamento farmacológico , Bevacizumab/uso terapêutico , Inibidores da Angiogênese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA